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resistance. However, the present study highlights
the importance of continuous monitoring of sus-
ceptibility patterns in order to observe the devel-
opment of resistance over a period of time. Such
laboratory-based data will be of immense value in
countries, such as India, where there are no
controls on the prescription and use of antibiotics
in the community.
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ABSTRACT
Between January 2002 and December 2003, macro-
lide-resistant isolates of Staphylococcus aureus
(n = 45) and coagulase-negative staphylococci
(CoNS; n = 75) from a Greek hospital were
examined phenotypically for inducible clindamy-
cin resistance. The constitutive macrolide resist-
ance phenotype predominated (60%) in S. aureus,
followed by the inducible (35%) and the clinda-
mycin-susceptible (5%) phenotypes. In CoNS, the
inducible phenotype was more common than the
constitutive phenotype (50% vs. 41%). There was
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a signiﬁcant incidence of inducible clindamycin
resistance, and screening of all staphylococci
is necessary in order to differentiate inducibly
resistant isolates from those that are truly sensi-
tive.
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Staphylococcus aureus and coagulase-negative sta-
phylococci (CoNS) have been recognised world-
wide as important causes of nosocomial and
community-acquired infections. The increasing
prevalence of methicillin resistance among sta-
phylococci is an increasing problem, and clinda-
mycin is considered to be one of the alternative
agents available to address this issue. In staphy-
lococci, macrolide resistance is usually caused
either by ribosomal modiﬁcation mediated by 23S
rRNA methylases encoded by the erm genes [1],
or by active efﬂux of the antimicrobial agent by an
ATP-dependent pump encoded by the msrA gene
[2]. Methylases confer inducible (iMLSB) or
constitutive (cMLSB) resistance to macrolides,
lincosamides and type B streptogramin agents
(MLSB resistance), while the efﬂux mechanism
affects macrolides and type B streptogramins
only. Other more rare macrolide resistance mech-
anisms include ribosomal mutations and anti-
biotic inactivation by speciﬁc hydrolases or
phosphotransferases [3,4].
Three macrolide resistance phenotypes have
been described in staphylococci, based on their
susceptibility to clindamycin, namely constitutive
resistance, inducible resistance and susceptibility.
In vitro tests show that strains with constitutive
resistance are resistant to all macrolides (14-, 15-
and 16-membered rings), lincosamides and strep-
togramin B, while inducibly-resistant strains
are resistant only to 14- and 15-membered-ring
macrolides. Broth dilution susceptibility tests fail
to detect inducible resistance, but this phenotype
can be detected by the double-disk diffusion test,
which is an induction test using closely posi-
tioned erythromycin and clindamycin disks [5].
The objective of the present study was to investi-
gate MLSB resistance phenotypically and to
record the current trend regarding the incidence
and distribution of inducible clindamycin resist-
ance in clinical isolates of S. aureus and CoNS
from Greece.
In 2003, the prevalence of community-acquired
methicillin-resistant S. aureus (MRSA) in the
Laconia area was 18.7%, with a higher and
increasing frequency (36.2%) of hospital-acquired
MRSA. The frequency of erythromycin resistance
in hospital-acquired MRSA was signiﬁcantly
higher than in community-acquired MRSA (25%
vs. 12%). In total, 120 consecutive, erythromycin-
resistant, clinical isolates of staphylococci (45
S. aureus and 75 CoNS) were recovered from
wounds, pus, catheters, urine and blood cultures
at the General Hospital of Sparta (Laconia,
Greece) during the period 2002–2003. Erythromy-
cin-resistant community-acquired MRSA isolates
were obtained from four patients with skin
abscesses, while the other 41 (91%) S. aureus
isolates were hospital-acquired MRSA strains.
Identiﬁcation to the species level was achieved
by catalase test, Gram’s stain, mannitol fermenta-
tion, growth on NaCl 6.5% w ⁄ v, latex slide
agglutination assay for detection of clumping
factor ⁄protein A ⁄ capsular polysaccharides (Sta-
phytect Plus; Oxoid, Basingstoke, UK), coagulase
tube test and, for CoNS, the API Staph system
(bioMe´rieux, Marcy-L’Etoile, France). Antibiotic
susceptibility testing was performed by the
NCCLS disk diffusion method with Mueller–
Hinton agar, an inoculum of 0.5· McFarland
standard, and incubation for 18 h at 35C (24 h for
oxacillin) in ambient air [6]. Methicillin resistance
was detected with an oxacillin 1-lg disk (Bio-Rad,
Marnes La Coquette, France), while PBP2¢ was
detected by a latex slide agglutination assay
(Slidex MRSA detection; bioMe´rieux).
All erythromycin-resistant, clindamycin-
susceptible isolates were also tested by the dou-
ble-disk test to determine the macrolide resistance
phenotype. Disks of erythromycin (15 lg) and
clindamycin (2 lg) were placed 16 mm apart
(edge to edge) [7,8]. Isolates with the clindamy-
cin-susceptible phenotype demonstrated erythro-
mycin resistance with clindamycin susceptibility,
while isolates with the inducible resistance phe-
notype were erythromycin-resistant with a ﬂat-
tening or blunting of the clindamycin zone in the
area between the two disks (D-shaped zone).
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Statistical analysis was by the chi-square test with
Yates’s correction, with the level of statistical
signiﬁcance deﬁned as p < 0.05.
Most (60%) of the S. aureus isolates had the
constitutive phenotype, but 35% had the indu-
cible phenotype, and only 5% had the clinda-
mycin-susceptible phenotype. The constitutive
phenotype predominated over the inducible
phenotype (75% vs. 25%) among the MRSA
isolates, and the clindamycin-susceptible pheno-
type was found only among methicillin-suscept-
ible S. aureus isolates. Without the double-disk
test, all S. aureus isolates with inducible clinda-
mycin resistance would have been misclassiﬁed
as clindamycin-susceptible, resulting in an under-
estimated clindamycin resistance rate of 60%
instead of 95%.
The distribution of macrolide resistance phe-
notypes among CoNS isolates revealed a higher
incidence of the inducible phenotype than the
constitutive phenotype (50% vs. 41%). In partic-
ular, for Staphylococcus epidermidis, the species
cultured most frequently from clinical samples,
55% of the isolates had the inducible phenotype
and no isolate with the clindamycin-susceptible
phenotype was observed. A statistically signiﬁ-
cant association between methicillin resistance
and the constitutive phenotype was observed for
S. aureus (p < 0.05) and S. epidermidis (p < 0.001)
isolates. The macrolide resistance phenotypes
found in the S. aureus and CoNS isolates following
the double-disk induction test are summarised in
Table 1.
Overall, the results indicated that there was a
high incidence of the inducible MLSB resistance
phenotype among S. aureus andCoNS isolates. The
double-disk test was necessary to discriminate
inducible clindamycin resistance from susceptibil-
ity to clindamycin correctly. The clindamycin-
susceptible phenotype was less common among
both S. aureus and CoNS isolates, but erythromy-
cin-resistant staphylococci should not be assumed
to be clindamycin-resistant. The incidence ofMLSB
resistance varies signiﬁcantly according to
geographical region. In Europe, there is a high
incidence (93%) of the constitutive phenotype in
MRSA, while the inducible phenotype is predom-
inant in methicillin-susceptible S. aureus [9–11]. In
contrast, a study from the USA reported a high
incidence of the clindamycin-susceptible pheno-
type in S. aureus (50%) and in CoNS isolates (33%)
[8].
Clindamycin resistance can develop in sta-
phylococcal isolates with the inducible pheno-
type, and spontaneous constitutively resistant
mutants have been selected from such isolates
both in vitro and in vivo during clindamycin
therapy [12–14]. The 2004 NCCLS guidelines
recommend use of the double-disk test and
suggest that isolates with the inducible resistance
phenotype should be reported as clindamycin-
resistant (with an optional comment). However,
the clinical efﬁcacy of clindamycin treatment for
infections caused by inducibly resistant staphylo-
cocci remains unclear. The few cases reported so
far have presented conﬂicting results, and elim-
ination of a potentially useful drug such as
clindamycin is not desirable, especially for the
treatment of MRSA infections [15]. Additional
clinical investigations are needed to determine
whether or not staphylococci with the inducible
phenotype should be reported as clindamycin-
resistant. Clinical microbiology laboratories
should use the double-disk test as standard
practice with all erythromycin-resistant staphylo-
cocci, in order to identify the precise macrolide
resistance phenotype and enable clinicians to be
informed about the possibility of clindamycin
treatment failure in patients with infections
caused by inducibly resistant strains.
Table 1. Prevalence of macrolide
resistance phenotypes in Staphylo-
coccus aureus and coagulase-negative
staphylococci from Greece Species n
Constitutive n (%) Inducible n (%)
Clindamycin-sus-
ceptible n (%)
MR MS MR MS MR MS
S. aureus 45 21 (47) 6 (13) 7 (15) 9 (20) 0 2 (5)
S. epidermidis 53 22 (41) 2 (4) 11 (21) 18 (34) 0 0
S. haemolyticus 11 6 (55) 0 2 (18) 2 (18) 1 (9) 0
S. saprophyticus 5 0 0 0 3 (60) 0 2 (40)
S. lugdunesis 4 0 0 1 (25) 0 2 (50) 1 (25)
S. hominis 2 1 (50) 0 0 0 0 1 (50)
MR, methicillin-resistant; MS, methicillin-susceptible.
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